Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas

Leukemia and Lymphoma

Volumn 51, Issue 5, 2010, Pages 813-821

  Watanabe, Takashi ^a   Kinoshita, Tomohiro ^b   Itoh, Kuniaki ^c   Yoshimura, Kenichi ^d   Ogura, Michinori ^e   Kagami, Yoshitoyo ^f   Yamaguchi, Motoko ^g   Kurosawa, Mitsutoshi ^h   Tsukasaki, Kunihiro ⁱ   Kasai, Masaharu ^j   Tobinai, Kensei ^a   Kaba, Harumi ^d   Mukai, Kiyoshi ^k   Nakamura, Shigeo ^l   Ohshima, Koichi ^m   Hotta, Tomomitsu ⁿ   Shimoyama, Masanori ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g MIE UNIVERSITY   (Japan)

^h HOKKAIDO CANCER CENTER   (Japan)

ⁱ NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^j SAPPORO HOKUYU HOSPITAL   (Japan)

^k TOKYO MEDICAL UNIVERSITY   (Japan)

^l NAGOYA UNIVERSITY HOSPITAL   (Japan)

^m KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

International Prognostic Index; Peripheral T cell lymphoma; Total protein; WHO classification

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PLASMA PROTEIN; PREDNISOLONE; VINCRISTINE;

ADULT; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; T CELL LYMPHOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PROTEINS; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, EXTRANODAL NK-T-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951805008     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003721359     Document Type: Article

References (38)

1. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
2. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000;50:696-702.
3. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
4. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer Press; 2001.
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
6. Ansell SM, Habermann TM, Kurtin PJ, et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997;15:2296-2301.
7. Sonnen R, Schmidt WP, Mü ller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005;129:366-372.
8. López-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R. E. A. L. Classification. Ann Oncol 1998;9:849-855.
9. Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. J Clin Oncol 1988;6:128-141.
10. Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990;1:45-50.
11. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997;89:4514-4520.
12. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998;92:76-82.
13. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U) : a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-2479.
14. Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de I'Adulte (GELA) trials. Blood 2008;111:4463-4470.
15. Kinoshita T, Hotta T, Tobinai K, et al. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate-or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. Int J Hematol 2004;80:341-350.
16. Mizoroki F, Hirose Y, Sano M, et al. A phase II study of VEPA/FEPP chemotherapy for aggressive lymphoma in elderly patients: Japan Clinical Oncology Group Study JCOG9203. Int J Hematol 2006;83:55-62.
17. Itoh K, Ohtsu T, Fukuda H, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002;13:1347-1355.
18. Tobinai K, Hotta T. Clinical trials for malignant lymphoma in Japan. Jpn J Clin Oncol 2004;34:369-378.
19. Hotta T, Shimakura Y, Ishizuka N, et al. Randomized phase III study of standard CHOP versus biweekly CHOP in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group study, JCOG9809. Proc Am Soc Clin Oncol 2003;22:2271a.
20. Shimoyama M, Oyama A, Tajima K, et al. Differences in clinicopathological characteristics and major prognostic factors between B-lymphoma and peripheral T-lymphoma excluding adult T-cell leukemia/lymphoma. Leuk Lymphoma 1993;10:335-342.
21. Rüdiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma) : results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13:140-149.
22. Armitage J, Vose J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
23. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913-3921.
24. Cheng AL, Chen YC, Wang CH, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989;7:725-731.
25. Hirose Y, Masaki Y, Sawaki T, et al. Association of Epstein-Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan. Eur J Haematol 2006;76:109-118.
26. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-1475.
27. Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007;109:2183-2189.
28. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24:2472-2479.
29. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-618.
30. Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood 2006;108:4163-4169.
31. Kojima H, Hasegawa Y, Suzukawa K, et al. Clinicopathological features and prognostic factors of Japanese patients with 'peripheral T-cell lymphoma, unspecified' diagnosed according to the WHO classification. Leuk Res 2004;28:1287-1292.
32. Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 2005;29:1284-1293.
33. Tsuchiya T, Ohshima K, Karube K, et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004;103:236-241.
34. Ohshima K, Karube K, Kawano R, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis. Int J Oncol 2004;25:605-613.
35. Cuadros M, Dave SS, Jaffe ES, et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 2007;25:3321-3329.
36. Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007;18:1382-1387.
37. Kim WY, Jeon YK, Kim TM, et al. Increased quantity of tumorinfiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol 2009;20:1688-1696.
38. Rodríguez J, Conde E, Gutiérrez A, et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007;92:1067-1074.